

# lenacapavir film-coated tablets and solution for injection (Sunlenca®)

Gilead Sciences Ltd

07 June 2024

**ADVICE:** in the absence of a submission from the holder of the marketing authorisation lenacapavir (Sunlenca®) is not recommended for use within NHSScotland.

**Indications under review:**

**Film-coated tablets:** in combination with other antiretroviral(s) for the treatment of adults with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen, for oral loading prior to administration of long-acting lenacapavir injection.

**Solution for injection:** in combination with other antiretroviral(s) for the treatment of adults with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in these indications. As a result, we cannot recommend its use within NHSScotland.

**Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

**Chair  
Scottish Medicines Consortium**